Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval
ISBN/ASIN: 9781461581543,9781461581529,0896034607 | 1997 | English | pdf | 311/315 pages | 14.9 Mb
Publisher: Humana Press | Author: Michel Pagé PhD (auth.), Beverly A. Teicher (eds.) | Edition: 1
Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe in Dr. Beverly Teicher's Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval the arduous process of cancer drug discovery and approval. The expert contributors focus on using in vivo and in vitro methods preclinically to identify molecules of interest, detailing the targets and criteria for success in each type of testing, and defining the value of the information obtained from the various tests. They also define each stage of clinical testing, explain the criteria for success, and outline the requirements for FDA approval. A companion volume by the same editor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies.
Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval offers cancer researchers an authoritative survey rich in essential insight into the means and methods of cancer drug discovery and approval. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for present and future developments in the field.